Drug copies ready to take next bite out of Roche's cancer sales

LONDON (Reuters) - European oncologists will soon get their hands on cut-price copies of breast cancer drug Herceptin, turning the screws on maker Roche and giving another boost to a new breed of companies focused on so-called biosimilars.